Kaleido Biosciences is a healthcare company that focuses on developing microbiome metabolic therapies for a range of conditions, such as urea cycle disorder, ulcerative colitis, hepatic encephalopathy, and COVID-19. In addition, it has programs in development for the treatment of various other conditions, including multi drug resistant infection and inflammatory bowel diseases. The company collaborates with Institute Gustave Roussy, Washington University, and Janssen, and was founded in 2015, with its main office located in Lexington, Massachusetts.